On July 8, 2025, Needham analyst Gil Blum reiterated a "Buy" rating for CRISPR Therapeutics (CRSP, Financial). The firm maintained its price target at $81.00 USD, which remains unchanged from the previous assessment.
CRISPR Therapeutics (CRSP, Financial), listed on the NASDAQ, continues to hold its ground with a steady outlook from Needham. The analyst's decision to uphold the "Buy" rating and consistent price target indicates ongoing confidence in the company's market performance and potential growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.80 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 57.84% from the current price of $51.19. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $36.68, suggesting a downside of 28.35% from the current price of $51.19. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
